Evidence map›Paper›PMID 40436639›Full record

ReviewJournal of Zhejiang University. Science. B2025

Recent advances in antibody optimization based on deep learning methods.

Ruofan Jin, Ruhong Zhou, Dong Zhang

Abstract readReview
In one paragraph

Review in Journal of Zhejiang University. Science. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ruofan JinInstitute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
Ruhong ZhouInstitute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China. rhzhou@zju.edu.cn.
Dong ZhangInstitute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China. rhzhou@zju.edu.cn, zhangd_iqb@zju.edu.cn.

Funding

the National Independent Innovation Demonstration Zone Shanghai Zhangjiang Major Projects ZJZX2020014the National Key R&D Program of China 2021YFF1200404 and 2021YFA1201200the National Natural Science Foundation of China 12104396the Shanghai Artificial Intelligence Lab P22KN00272the Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University SN-ZJU-SIAS-003
6 · The paper itself

Abstract

Antibodies currently comprise the predominant treatment modality for a variety of diseases; therefore, optimizing their properties rapidly and efficiently is an indispensable step in antibody-based drug development. Inspired by the great success of artificial intelligence-based algorithms, especially deep learning-based methods in the field of biology, various computational methods have been introduced into antibody optimization to reduce costs and increase the success rate of lead candidate generation and optimization. Herein, we briefly review recent progress in deep learning-based antibody optimization, focusing on the available datasets and algorithm input data types that are crucial for constructing appropriate deep learning models. Furthermore, we discuss the current challenges and potential solutions for the future development of general-purpose deep learning algorithms in antibody optimization.

Indexed as

AntibodiesDeep LearningAlgorithmsArtificial IntelligenceDrug DevelopmentHumansAntibodiesAntibody optimizationAvailable datasetDeep learningInput data type

Identifiers

PMID40436639
PMCPMC12119181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.